Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Research & Development - Clinical Trials
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Bioprojet's orphan drug for EDS enters Phase III trials
16 March 2010
The privately owned French biotech firm Bioprojet says that its new compound for excessive daytime sleepiness (EDS), pitolisant, has shown good results in several European Phase II trials and has now begun Phase III development. The product, which ...
Pfizer faces disappointment with anticancers after more Phase III failures
12 March 2010
Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in advanced breast cancer - ending development for the drug in the disease - and figitumumab ...
New Singapore centre to bolster Asian cancer trials
12 March 2010
Singapore has launched a new national cancer centre which it expects to play a key role in the advancement of novel therapies for malignancies prevalent in the Asia-Pacific region. The National University Cancer Institute, Singapore, was formally ...
Europe to give €12 million for influenza antiviral projects
12 March 2010
The European Commission will provide €12 million in funding for two new research projects which will develop novel influenza treatments, including against both (A) H1N1 pandemic influenza and (A) H5N1 avian flu. Speaking at an EU influenza meeting ...
PTC Therapeutics/Genzyme's ataluren fails in Phase IIb muscular dystrophy trial
11 March 2010
PTC Therapeutics and Genzyme 's ataluren, an experimental nonsense mutation suppressor, has failed in nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD), show top-line Phase IIb results. Around 10-15% of DBMD cases are due to nonsense ...
 
Market Insight - Differentiation guiding firms through maze of hepatitis C drug development
22 January 2010
The therapeutic landscape in HCV treatment is at an inflection point – recent data from the first generation of protease inhibitors promise the dawn of a new standard of care. But do not expect to ...
2010 Scrip 100 - Steps and strides forward for MS
09 December 2009
Several promising new multiple sclerosis drugs are poised to make their debut on the market within the next few years. What effect will they have on the treatment paradigm for this debilitating ...
2010 Scrip 100 - Unleashing the power of the immune system to fight cancer
09 December 2009
Recent developments in the field of active cancer immunotherapy foreshadow that the "next big thing" in cancer drugs may be on the way. Yet appropriately designed clinical trials testing combination ...
 
Anti-obesity drugs: an inventor's perspective
20 November 2009
After years of anti-obesity disappointments, Orexigen's Contrave, Vivus's Qnexa and Arena's lorcaserin stand on the verge of being filed with the US FDA. Professor Michael Cowley, inventor of ...
Face-to-face: Evotec CEO tells of turnaround
02 October 2009
Since becoming CEO of Evotec Dr Werner Lanthaler has overseen a string of deals as well as upheavals at the company. He spoke to Scrip's Simon Varcoe about how the German firm has been transformed ...
Face-to-face with Abingworth's Stephen Bunting:we've had time to adapt to tough markets
25 August 2009
While many venture capital (VC) firms have dropped beneath the radar during the current credit squeeze, Abingworth is one of the few that is not just visible but appears to be operating on a business ...
 
GSK's malaria vaccine sails towards uncharted territory
05 November 2009
GlaxoSmithKline will enter unknown regulatory waters when it eventually comes to seek approval of its paediatric malaria vaccine, RTS,S, the most advanced in development for this disease. The ...
Private investment round-up: June 2009
22 July 2009
The total investments secured by private companies slumped once more in June, disappointing onlookers hoping that May's healthy performance was a sign of recovery in the market, a Scrip analysis has ...
Cancer drugs: getting more for your money – by Karol Sikora
11 May 2009
Cancer treatment is undergoing a revolution, driven by ageing populations, advanced technologies and an increasingly informed society. Health economics considerations and top-up payments are gaining ...
 
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
01 December 2008
For the last half-century, despite its many limitations warfarin has been the mainstay of treatment for patients with venous and arterial thromboembolic disease. During the past decade, a number of ...
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
01 December 2008
mTOR was determined to be a promising anticancer target and several drug inhibitors of mTOR are currently in clinical development. Rapamycin (RAP) was the first mTOR inhibitor discovered. However, ...
Emerging oral drugs for multiple sclerosis
01 September 2008
Background: Therapy for multiple sclerosis (MS) has changed dramatically over the past decade, yielding significant progress in the treatment of relapsing/remitting and secondary progressive MS. ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm